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Key Points
• This study defined similarities and differences in gastroparesis severity, healthcare utilization, psychological
function, and quality of life in patients with type 1 (T1DM) and type 2 (T2DM) diabetes mellitus and
gastroparesis.
• At baseline enrollment into the NIDDK Gastroparesis Clinical Research Consortium Registry, T1DM patients
had higher hemoglobin A1c (HbA1c) levels and more severe emptying delays, but the severity of GI symptoms
was similar to those of patients with T2DM and gastroparesis.
• After 48 weeks of follow-up in the Registry, gastroparesis symptom scores significantly decreased in T2DM
patients but not in T1DM patients despite increased use of prokinetic, acid suppressant, anxiolytic, and gastric
electrical stimulation therapy in the T1DM group.
• Explanations for these differences in clinical outcomes at 48 weeks in patients with gastroparesis due to T1DM
vs T2DM require further investigation.
Abstract
Background In studies of diabetic gastroparesis,
patients with type 1 and type 2 diabetes mellitus
(T1DM, T2DM) are often combined for analyses. We
compared gastroparesis severity, healthcare utiliza-
tion, psychological function, and quality of life in
T1DM vs T2DM gastroparesis patients. Methods
Questionnaire, laboratory, and scintigraphy data
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from patients with gastroparesis and T1DM and
T2DM from seven centers of the National Institute
of Diabetes and Digestive and Kidney Diseases
Gastroparesis Clinical Research Consortium Registry
were compared at enrollment and after 48 weeks.
Multiple regression models assessed baseline and
follow-up differences between diabetes subtypes.
Key Results At baseline, T1DM patients (N = 78)
had slower gastric emptying, more hospitalizations,
more gastric stimulator implantations, higher hemo-
globin A1c (HbA1c), and more anxiety vs T2DM
patients (N = 59). Independent discriminators of
patients with T1DM vs T2DM included worse
gastroesophageal reflux disease, less bloating, more
peripheral neuropathy, and fewer comorbidities
(p ≤ 0.05). On follow-up, gastrointestinal (GI) symp-
tom scores decreased only in T2DM (p < 0.05), but
not in T1DM patients who reported greater proki-
netic, proton pump inhibitor, anxiolytic, and gastric
stimulator usage over 48 weeks (p ≤ 0.03). Gastroin-
testinal symptoms at baseline and 48 weeks with
both subtypes were not associated with HbA1c,
peripheral neuropathy, psychological factors, or qual-
ity of life. Conclusions & Inferences Baseline symp-
toms were similar in T1DM and T2DM patients, even
though T1DM patients had worse gastric emptying
delays and higher HbA1c suggesting other factors
mediate symptom severity. Symptom scores at
48 weeks decreased in T2DM, but not T1DM
patients, despite increased medical and surgical
treatment utilization by T1DM patients. Defining
causes of different outcomes in diabetic gastroparesis
warrants further investigation.
Keywords gastric emptying, gastroparesis,
hyperglycemia, nausea and vomiting, type 1 and type
2 diabetes mellitus.
Abbreviations: BDI, Beck Depression Inventory; BMI,
body mass index; CRP, C-reactive protein; ED,
emergency department; ESR, erythrocyte sedimenta-
tion rate; GCSI, Gastroparesis Cardinal Symptom
Index; GERD, gastroesophageal reflux disease; GES,
gastric electrical stimulator; GI, gastrointestinal;
GpCRC, Gastroparesis Clinical Research Consortium;
HbA1c, hemoglobin A1c; NIDDK, National Institute
of Diabetes and Digestive and Kidney Diseases;
PAGI-QOL, Patient Assessment of Upper Gastroin-
testinal Disorders Quality of Life; PAGI-SYM, Patient
Assessment of Upper Gastrointestinal Disorders Symp-
toms; SF-36v2, Short Form-36v2; STAI, State and Trait
Anxiety Inventory; T1DM, type 1 diabetes mellitus;
T2DM, type 2 diabetes mellitus; TPN, total parenteral
nutrition.
INTRODUCTION
Diabetic gastroparesis is associated with nausea, vom-
iting, fullness, bloating, early satiety, and epigastric
discomfort/pain and is diagnosed by documenting
delayed gastric emptying.1–5 However, emptying delays
correlate poorly with symptoms, suggesting other
pathogenic factors influence symptoms. These factors
include: (i) chronic hyperglycemia, which acutely
impairs gastric neuromuscular function; (ii) gastric
factors ranging from impaired fundic accommodation
to gastric electrical dysrhythmias; and (iii) psycholog-
ical dysfunction, which is prevalent in diabetic gastro-
paresis.6–12 Gastroparesis is thought to contribute to
poor glycemic control which results in ketoacidosis
and other complications that increase hospitalizations
and outpatient visits and costs.13,14 Longitudinal stud-
ies suggest diabetic gastroparesis follows an indolent
course with stable gastrointestinal (GI) symptoms and
emptying rates over 25 years, although increased mor-
tality has been reported.15–17 Furthermore, a recently
published study observed no differences in overall
symptom improvements over 48 weeks in patients
with diabetic vs idiopathic gastroparesis.18
Type 1 diabetes mellitus (T1DM) from failed insulin
production is distinct from type 2 disease (T2DM)
which is due to insulin resistance and variable insulin
release deficits.19,20 Type 1 diabetes mellitus requires
insulin therapy, while T2DM is managed with diet and
oral medications in milder cases and insulin in more
severe cases. Gastroparesis is reported in 27–58% of
T1DM patients vs 20–40% with T2DM; the 10-year
incidence of gastroparesis is five times higher with
T1DM (5.2% vs 1.0%).21–24 Gastroparesis is associated
with increased hemoglobin A1c (HbA1c) levels and
diabetic complications (retinopathy, neuropathy) in
T1DM, while obesity status has been associated with
symptoms in T2DM with gastroparesis.25,26 Compre-
hensive comparisons of clinical profiles, comorbidities,
disease severity, resource utilization, psychological
dysfunction, quality of life, and clinical courses in
patients with gastroparesis and T1DM vs T2DM have
not been performed.
Our aim was to compare the clinical features of
patients with gastroparesis and T1DM and T2DM at
baseline enrollment into the National Institute of
Diabetes and Digestive and Kidney Diseases Gastro-
paresis Registry and after 48 weeks of follow-up during
which time the patients’ GI symptoms were managed
by gastroenterologists at tertiary centers. We hypoth-
esized that patients with T1DM gastroparesis at base-
line have (i) more severe GI symptoms, (ii) more
severely delayed gastric emptying, (iii) poorer glycemic
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control, (iv) more peripheral neuropathy, (v) more
healthcare utilization, and (vi) more impaired psycho-
logical dysfunction and quality of life compared with
patients with T2DM and gastroparesis. We further
hypothesized that symptoms, psychological function,
and quality of life would show similar longitudinal




Seventy-eight patients with T1DM and 59 patients with T2DM
and gastroparesis in the Gastroparesis Clinical Research Consor-
tium (GpCRC) Registry were identified. Each patient completed
validated surveys and underwent examinations and blood testing
on enrollment and at 48-week follow-up visits from January 2007
to May 2011 (ClinicalTrials.gov Identifier: NCT00398801). All
subjects reported symptoms associated with gastroparesis for at
least 12 weeks duration (not necessarily contiguous weeks) and
had gastroparesis defined by scintigraphy (>60% retention at 2 h
and/or >10% retention at 4 h) within 6 months of enrollment.5
Prokinetics, opiates, anticholinergics, and other agents that affect
gut transit were stopped at least 72 h before gastric emptying
testing. Upper endoscopy performed within 1 year of Registry
enrollment showed no evidence of organic causes of symptoms.
Patients with ulcers, malignancy, mechanical obstruction, active
inflammatory bowel disease, eosinophilic gastroenteritis, neuro-
logic disease, hepatic or renal disease, other metabolic disease, or
prior gastroesophageal surgery were excluded. The determination
of T1DM vs T2DM status and the diagnosis of diabetic gastro-
paresis were made by each site investigator based upon patient
reports and review of records. Studies were approved by Institu-
tional Review Boards at each Clinical Center and Data Coordi-
nating Center. Patients provided written informed consent.
Data acquisition
Survey completion, examinations, and local laboratory blood
testing were performed on enrollment and 48-week follow-up
visits. Demographic and medical information was collected on
Registration and Baseline Medical History forms (Data S1),
including self-reported clinician-diagnosed peripheral neuropathy.
Body mass index (BMI) was calculated at both times from physical
examination data; numbers and percentages who were overweight
or obese (≥25 kg/m2) were calculated. Numbers and percentages
with any comorbidity and numbers of comorbidities were deter-
mined on enrollment (Data S1). As inflammatory activation has
been identified in some cases of gastroparesis, C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR) were measured on
enrollment as non-specific markers of inflammation27; numbers
and percentages with elevated CRP (>0.8 mg/dL) and ESR values
(>20 mm/h) were determined; any inflammation was defined as
either an elevated CRP and/or elevated ESR. Hemoglobin A1c was
quantified at both visits; numbers and percentages of patients
with HbA1c values <8% vs ≥8% were defined.
Gastroparesis severity was quantified in four ways: (i) investi-
gator-rated gastroparesis severity was assessed on enrollment and
at 48 weeks by each principal investigator using an expert
consensus stratification (Supplemental Methods)2; (ii) Patient
Assessment of Upper Gastrointestinal Disorders Symptoms
(PAGI-SYM) questionnaires were used to quantify 20 individual
symptoms that the patient scored from 0 (none) to 5 (most
severe)28; (iii) overall symptom severity was determined by total
scores from the Gastroparesis Cardinal Symptom Index (GCSI;
Data S1)29; and (iv) percentages of test meal retained at 4 h from
pre-enrollment scintigraphy studies were used to stratify results
into mild (11–20%), moderate (21–35%), and severe (>35%
retained) gastric emptying delays.30
Medication use was queried on enrollment and at 48 weeks
(Data S1). Numbers and percentages of T2DM patients taking
antidiabetic medications known to cause nausea and vomiting
were determined.25 Symptoms were compared in patients who
were taking vs not taking these agents on enrollment.
Health utilization parameters were determined. On enroll-
ment, patients reported how many times they were hospitalized
over the prior year and for what reasons they were hospitalized. At
48 weeks, they were asked how many times they had required
emergency department (ED) evaluation or hospitalization solely
for gastroparesis since enrollment (excluding gastric electrical
stimulator [GES] implantation). Numbers and percentages of
patients on total parenteral nutrition (TPN) and who had under-
gone GES implantation were determined at baseline and
48 weeks.
Measures of psychological dysfunction and quality of life were
quantified. Depression and anxiety were enumerated by the Beck
Depression Inventory (BDI) and State and Trait Anxiety Inventory
(STAI; Data S1).31,32 Numbers and percentages with severe
depression (BDI score >28), state anxiety (Y1 score ≥50), and trait
anxiety (Y2 score ≥50) were calculated. Disease-specific and
generic quality of life was assessed by Patient Assessment of
Upper Gastrointestinal Disorders Quality of Life (PAGI-QOL) and
Short Form-36v2 (SF-36v2) surveys, respectively (Data S1).33,34
Enrollment (baseline) symptom scores were subtracted from
48-week values to calculate changes in all measures. Baseline
BMI, HbA1c, hospitalizations for gastroparesis, patients on TPN
or undergoing GES, BDI, Y1, Y2, and quality of life scores were
subtracted from 48-week levels to quantify changes. Numbers and
percentages of patients on different medications at baseline were
subtracted from 48-week values to estimate changes.
Statistical methodologies
Number and percentages or means  SD were reported for
enrollment categorical or continuous characteristics. p values
were determined from Pearson chi-squared or Fisher’s exact tests
for categorical characteristics and Kruskal–Wallis tests to account
for non-normality of continuous distributions.35 Baseline discrim-
inators of diabetes subtype were determined from backward
stepwise multiple logistic modeling regressing diabetes subtype
on the 46 baseline characteristics, forcing age at enrollment, sex,
and white race into the model, with p for exclusion = 0.05.36
Total number rather than individual comorbidities was included;
GCSI was excluded due to collinearity. Hosmer–Lemeshow
testing revealed adequate fit for the model (p = 0.71). Differences
between patients completing 48-week follow-up vs patients with
only enrollment data were assessed using multiple logistic
regression of 48-week completion on baseline characteristics
(diabetes subtype, demographics, BMI, severity, medications
[prokinetics, opiates, antidepressants], healthcare utilization,
psychological function, quality of life). Mean changes  SD at
48 weeks vs enrollment were computed for all characteristics
except ED visits (not queried on enrollment). For continuous
characteristics, p values were determined using one sample t-tests
of the null hypothesis of no difference in means at both visits
© 2016 John Wiley & Sons Ltd 1003
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within diabetes subtype comparisons. For binary characteristics
and medication changes, exact McNemar’s tests for paired
proportions were used to determine p and 95% confidence
intervals (CI) which were computed using continuity correc-
tions.37,38 Multiple regression models of 48-week changes in
continuous characteristics, adjusting for enrollment values,
assessed changes between diabetes subtype (except for ED
visits).39 Negative binomial regressions (to account for overdis-
persion) of ED visits over 48 weeks on diabetes subtypes were
used. Wald’s tests using conditional logistic regression tested if
48-week changes in hospitalizations for gastroparesis or medica-
tion use varied by subtype.36 Unconditional exact logistic regres-
sion assessed TPN use and GES changes with T2DM. Relative
odds of changes in 48-week outcomes were derived from logistic
regression models of each indicator at 48 weeks in relation to
subtype and enrollment value of the indicator. Models included
propensity scores to adjust diabetes subtype effects for probabil-
ities of being T1DM based on age, sex, and race.40 Outcome
indicators defined by 48-week changes from enrollment included
any symptom score decrease, no change or decreased BMI, any
HbA1c decrease, ≥5 point BDI decrease, any STAI decrease, and
any QOL increase. Healthcare utilization reductions were defined
as no hospitalizations or ED visits for gastroparesis over 48 weeks.
Given the exploratory nature of our study, p values were two-
sided and nominal with significance at the p = 0.05 level, a priori.
Because a goal of these exploratory analyses was to generate new
hypotheses to be tested in future confirmatory studies, correction
for multiple comparisons was not performed. Such adjustments
reduce the power of an investigation to define important differ-
ences, are unnecessary if exploratory research questions are
unrelated, and are only required for studies which aim to offer
decisive proof of a predefined hypothesis to endorse decision-
making protocols.41–43 Stata (Stata Statistical Software, Release
v12; StataCorp LP, College Station, TX, USA) and SAS (version
9.3; SAS Institute, Inc., Cary, NC, USA) software were employed.
RESULTS
Demographic and clinical factors at baseline
Demographic and clinical factors and comorbidities for
the T1DM and T2DM patients with gastroparesis at
baseline are shown in Table 1. Type 2 diabetes melli-
tus patients with gastroparesis had several expected
differences compared with T1DM patients. These
T2DM patients were older at enrollment and at the
onset of GI symptoms, had higher BMIs, and were
more often overweight, obese, or postmenopausal
(p < 0.001). Type 1 diabetes mellitus patients reported
longer durations of diabetes prior to the onset of
gastroparesis (p = 0.005). On average, HbA1c levels
were greater in T1DM patients by 0.9% (p = 0.003);
T1DM patients comprised larger proportions with
HbA1c levels ≥8% (37/53, 69.8%) vs <8% (38/81,
46.9%; p = 0.009). Almost all T1DM (98.7%) and
T2DM (98.3%) patients reported ≥1 comorbidity, but
numbers of comorbidities were higher with T2DM
(5.5  3.4 vs 4.0  2.8; p = 0.005). Coronary and cere-
brovascular disease and interstitial cystitis were sig-
nificantly more common in T2DM patients (p ≤ 0.05).
Type 2 diabetes mellitus patients more often under-
went hysterectomies (p < 0.001). Similar percentages
of T1DM vs T2DM patients reported peripheral neu-
ropathy (43.6% vs 37.3%, p = 0.46).
Comparisons of gastroparesis-related factors in
T1DM vs T2DM at baseline
Gastroparesis severity, GCSI results, and resource
utilization The most severe symptoms reported by
both T1DM and T2DM patients with gastroparesis
were nausea and postprandial fullness. Patients with
T1DM and gastroparesis were more often assigned by
the investigator to the severe gastroparesis category
(49% vs 39%) and less to the mild category (6% vs
16%) compared with T2DM patients (p = 0.05;
Table 2). However, patient-rated overall GCSI scores
were similar in T1DM and T2DM patients (2.8  1.1
vs 3.0  1.0, p = 0.28). Individual GI symptoms were
also similar, except for higher bloating symptoms in
T2DM patients (p = 0.04). More T1DM patients had
delayed emptying at 2 h (p = 0.006) and 4 h (p < 0.001)
after ingestion of the meal, and more T1DM patients
had severe emptying delays (>35% 4-h retention)
compared with T2DM patients (54% vs 32%,
p = 0.001).
Medication use from prokinetics to opiates was
similar in the two subtypes, except T2DM patients had
more metformin use (p < 0.001). Nineteen of 59 T2DM
gastroparetics (32%) used metformin on enrollment;
none were on other antihyperglycemic agents
(exenatide, liraglutide, pramlintide) that cause nausea.
Overall, GI symptoms were similar in the T2DM
patients who were taking metformin vs those patients
not taking metformin (p = 0.91), although vomiting
scores on average were lower in the group receiving
metformin at baseline by 1.0 point (p = 0.04; Table S1).
Type 1 diabetes mellitus patients reported more
hospitalizations in the year before enrollment solely
for gastroparesis (5.1  6.4 vs 3.2  6.6, p = 0.003), and
were hospitalized more often for nausea and vomiting
(p = 0.001), abdominal pain (p = 0.003), and dehydra-
tion (p = 0.01) compared with T2DM patients
(Table 2). Total parenteral nutrition use at baseline
was similar in the T1DM and T2DM patients
(p = 0.78). More T1DM patients underwent GES
implantation before enrollment in the GpCRC Regis-
try (15% vs 3%, p = 0.02).
Psychological function and quality of life More T1DM
patients with gastroparesis reported severe state
anxiety (Y1 score ≥50; p = 0.04) and although not
significant, more severe trait anxiety (Y2 score ≥50;
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p = 0.06) compared with T2DM patients. Other psy-
chological survey, overall PAGI-QOL, individual
PAGI-QOL domain, and SF-36v2 scores were similar
in the two diabetes subtypes (Table 2).
Relationships among gastroparesis factors, HbA1c
levels, and peripheral neuropathy on subgroup analy-
sis Table 3 shows investigator-rated severity of gastro-
paresis and patient-scored GCSI results in the two
subgroups according to baseline HbA1c values <8% vs
≥8% and the presence or absence of peripheral neu-
ropathy. HbA1c groupings had no relationship with the
investigator ratings of gastroparesis severity, overall
GCSI scores and individual GI symptom scores. Delays
in gastric emptying at 2 or 4 h were not related to
HbA1c status (p = 0.96 or p = 0.79). Gastrointestinal
symptom severities (except for postprandial fullness)
were similar whether the T1DM and T2DM patients
did or did not report peripheral neuropathy. Investiga-
tor-rated gastroparesis severity and delays in gastric
emptying were similar regardless of peripheral neu-
ropathy status.
Characteristics that discriminated patients with
gastroparesis and T1DM vs T2DM at baseline Forty-
six baseline predictors were used in regression analyses
to determine clinical characteristics that distinguished
the T1DM and T2DM patients. Few baseline charac-
teristics discriminated the subtypes (Table 4). Com-
pared with T2DM gastroparesis patients, T1DM
patients were about one-third less likely to have more
severe bloating (OR = 0.62, p = 0.02) and almost twice






p Value*N % or mean  SD N % or mean  SD
Demographic/clinical Demographic Female sex 55 70.5% 45 76.3% 0.56
Age (years) 78 39  11 59 53  11 <0.001
White race 60 76.9% 45 76.3% 1.00
Hispanic ethnicity 7 9.0% 5 8.5% 1.00
Married 42 53.9% 38 64.4% 0.23
College degree 15 19.2% 12 20.3% 1.00
Income >$50K 36 46.2% 25 42.4% 0.73
Ever smoked regularly 23 29.5% 23 39.0% 0.28
Medical History Age at symptom onset (years) 78 34  10 59 49  11 <0.001
Time from diabetes onset to
initial symptoms (years)
78 14.0  11.0 59 8.4  8.0 0.005
Symptom duration (years) 78 6.2  6.3 59 3.9  3.3 0.13
Peripheral neuropathy 34 43.6% 22 37.3% 0.46
Acute onset 46 59.0% 27 45.8% 0.11
Initial infectious prodrome 11 14.1% 8 13.6% 1.00
Postmenopausal (if female) 12 21.8% 28 62.2% <0.001
Anthropometric BMI (kg/m2) 78 26  6 59 33  8 <0.001
Underweight 2 3% 0 0% <0.001
Normal 37 47% 8 14%
Overweight or obese 39 50% 51 86%
Laboratory CRP (mg/dl) 78 0.9  1.5 58 0.7  0.6 0.10
CRP elevated >0.8 mg/dl 20 25.6% 19 32.8% 0.36
ESR (mm/h) 78 26  24 59 28  25 0.53
ESR elevated >20 mm/h 37 47.4% 30 50.9% 0.69
Hemoglobin A1c (%) 78 8.3  2.0 59 7.4  1.7 0.003
Comorbidities Peptic ulcer disease 3 3.9% 5 8.5% 0.29
GERD 41 52.6% 38 64.4% 0.16
Gallstones/gallbladder disease 21 26.9% 25 42.4% 0.06
Coronary artery/cerebrovascular disease 6 7.7% 11 18.6% 0.05
Endometriosis 4 5.1% 7 11.9% 0.21
Interstitial cystitis 0 0.0% 4 6.8% 0.03
Prior hysterectomy 9 16.4% 22 48.9% <0.001
Migraine headaches 19 24.4% 22 37.3% 0.10
Chronic fatigue syndrome 4 5.1% 2 3.4% 0.70
Fibromyalgia 5 6.4% 7 11.9% 0.26
Major depression 22 28.2% 19 32.2% 0.61
Severe anxiety 8 10.3% 5 8.5% 0.72
*p (two-sided) determined from either a chi-squared test or Fisher’s exact test for categorical characteristics or a Kruskal–Wallis test to account for
non-normality of the continuous variables.
Bold values represent statistical significance p ≤ 0.05.
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p Value*N % or mean  SD N % or mean  SD
Gastroparesis
severity
Investigator-rated Grade 1 4 5.8% 9 15.5% 0.05
Grade 2 36 46.2% 27 46.6%
Grade 3 38 49.4% 23 39.0%
Patient-rated Overall GCSI 78 2.8  1.1 59 3.0  1.0 0.28
Nausea 78 3.4  1.3 59 3.2  1.2 0.20
Retching 78 2.4  1.7 59 2.5  1.7 0.99
Vomiting 78 2.7  1.8 59 2.4  1.7 0.30
Stomach fullness 78 3.2  1.6 59 3.6  1.0 0.27
Unable to finish meal 78 2.9  1.5 59 3.2  1.2 0.43
Postprandial fullness 78 3.3  1.5 59 3.5  1.3 0.80
Loss of appetite 78 2.8  1.6 59 2.8  1.4 0.96
Bloating 78 2.8  1.7 59 3.4  1.4 0.04
Visible distention 78 2.5  1.8 59 2.9  1.7 0.19
Upper abdominal pain 78 2.8  1.9 59 2.8  1.7 0.84
Upper abdominal discomfort 78 2.9  1.8 59 3.2  1.5 0.47
Lower abdominal pain 78 2.3  1.7 59 1.8  1.4 0.09
Lower abdominal discomfort 78 2.3  1.6 59 1.9  1.5 0.15
GERD 78 2.0  1.4 59 1.9  1.3 0.86
Constipation 78 2.3  1.7 59 2.4  1.6 0.71
Diarrhea 78 2.0  1.8 59 1.8  1.6 0.48
Gastric function 2-h retention 78 71  20% 59 61  22% 0.006
4-h retention 78 47  27% 59 33  24% <0.001
Mild retention
(11–20% 4-h retention)
14 18.0% 26 44.1% 0.001
Moderate retention
(21–35% 4-h retention)
22 28.2% 14 23.7%
Severe retention
(>35% 4-h retention)
42 53.9% 19 32.2%
Medications Prokinetics 54 69.2% 38 64.4% 0.55
Antiemetics 55 70.5% 40 67.8% 0.73
Proton pump inhibitors/other GI agents 62 79.5% 49 83.1% 0.60
NSAIDs 42 53.9% 40 67.8% 0.10
Opiates 36 46.2% 28 47.5% 0.88
Pain modulators 21 26.9% 17 28.8% 0.81
Antidepressants 33 42.3% 21 35.6% 0.43
Anxiolytics 7 9.0% 12 20.3% 0.06
Antidiabetics 74 94.9% 56 94.9% 1.00
Metformin 2 2.6% 19 32.2% <0.001
Health care
utilization
Hospitalized for gastroparesis in past year 57 73.1% 27 45.8% 0.001
Number of hospitalizations for gastroparesis in past year 78 5.1  6.4 59 3.2  6.6 0.003
Reason for hospitalization Nausea/vomiting 54 72.0% 25 43.9% 0.001
Abdominal pain 33 61.1% 15 31.9% 0.003
Dehydration 39 65.0% 22 40.7% 0.01
GI hemorrhage 6 22.2% 3 8.6% 0.16
On TPN 8 10.3% 5 8.5% 0.78
Underwent GES 12 15.4% 2 3.4% 0.02
Psychological
function
BDI 78 22  13 59 19  10 0.78
BDI score >28 20 25.6% 10 17.0% 0.22
Y1 state anxiety 78 48  14 59 45  13 0.19
Y1 score ≥50 37 47.4% 18 30.5% 0.04
Y2 trait anxiety 78 47  13 59 44  13 0.08
Y2 score ≥50 35 44.9% 17 28.8% 0.06
Quality
of life
Overall PAGI-QOL 78 2.4  1.1 59 2.6  1.2 0.23
PAGI-QOL subscore Daily activities 78 2.2  1.3 59 2.4  1.2 0.21
Clothing 78 3.0  1.7 59 3.0  1.7 1.00
Diet 78 1.7  1.2 59 1.8  1.3 0.71
Relationship 78 2.8  1.7 59 3.1  1.5 0.28
Psychological 78 2.4  1.5 59 2.8  1.4 0.08
SF-36v2 physical 78 33  10 59 30  9 0.11
SF-36v2 mental 78 34  12 59 37  13 0.16
*p (two-sided) determined from either a chi-squared test or Fisher’s exact test for categorical characteristics or a Kruskal–Wallis test to account for
non-normality of the continuous variables.
Bold values represent statistical significance p ≤ 0.05.
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as likely to have gastroesophageal reflux disease
(GERD) symptoms (OR = 1.70, p = 0.02). Type 1 dia-
betes mellitus patients were younger
(ORAge≥50yrs = 0.07, p < 0.001), had more peripheral
neuropathy (OR = 3.81, p = 0.02), had more than nine
times the odds of normal or underweight status
(OR = 0.11, p < 0.001), and reported approximately
25% fewer numbers of comorbidities (OR = 0.76,
p = 0.02) than T2DM patients with gastroparesis.
Clinical factors at 48 weeks
Ninety of 137 enrolled patients (66%) completed the
48-week visit: 44 patients with T1DM (56% of baseline
cohort) and 46 patients with T2DM (79% of the
baseline cohort). Compared to those with only enroll-
ment data, patients completing follow-up were more
often male, white race, and overweight and less likely
to have GES surgery (p ≤ 0.05); diabetic subgroup was
not associated with completing follow-up with adjust-
ment for all other characteristics (OR T1DM vs
T2DM = 0.35, p = 0.09; Table S2).
Body mass index did not change significantly over
the 48 weeks in these T1DM and T2DM patients as
shown in Table 5. Hemoglobin A1c levels increased
similarly, but not significantly, compared with base-
line over the 48 weeks in both T1DM and T2DM
patients (p = 0.51). Three patients with T1DM and one
with T2DM died during the 48-week period.
Comparisons of gastroparesis-related factors in
T1DM vs T2DM at 48 weeks
Gastroparesis severity, GCSI results, and resource
utilization Gastrointestinal symptom severity did
not decrease at 48 weeks in the patients with T1DM
as measured by GCSI and individual scores (Fig. 1A). In
contrast, overall GCSI scores and all individual symp-
toms (except postprandial fullness and visible disten-
tion) decreased significantly at 48 weeks in the T2DM
patients (Fig. 1B). Fig. 1C shows the changes in
patient-reported symptoms (95% CI) at 48 weeks for
both subtypes. Investigator-rated gastroparesis severity
ratings showed similar reductions from baseline
within T1DM (mean change = 0.33, p = 0.009) and
T2DM (mean change = 0.30, p = 0.02) patients; how-
ever, these changes were not different between the
subtypes (PT1DM vs T2DM = 0.23; Table 5).
Increased use of prokinetic drugs (+15.9%), proton
pump inhibitor/other GI agents (+13.6%), and anxi-
olytic drugs (+25.0%) was recorded in T1DM patients
(p ≤ 0.03), whereas increased use of opiates (+17.4%)
was documented in T2DM patients (p = 0.04) at
48 weeks compared with baseline (Table 5). Percent-
ages of patients hospitalized for gastroparesis during
the 48-week follow-up decreased 15.1% in the T1DM
patients (p = 0.04), but did not significantly change for
T2DM patients; however, decreases in hospitalizations
for T1DM vs T2DM patients were not significantly
different (p = 0.26). The number of ED visits and
changes in TPN use over 48 weeks were not different
between diabetes subtypes. Implantation of GES
devices increased 20.5% over 48 weeks in patients
with T1DM (p = 0.01) and increased 10.9% in T2DM
patients (p = 0.06). Including those who were
implanted before enrollment, more T1DM patients
were receiving GES after 48 weeks of follow-up com-
pared with patients with T2DM and gastroparesis
(31.9% vs 10.9%; p = 0.02).
Psychological function and quality of life No changes
in any psychological or quality of life parameter in
either subtype or between subtypes were observed at
48 weeks of follow-up (Table 5).
Table 4 Baseline clinical discriminators of diabetes subtype (T1DM vs T2DM) in patients with gastroparesis
Category Characteristic OR* 95% CI p value†
Demographic Age (≥50 vs <50 years) 0.07 0.02, 0.24 <0.001
Sex (female vs male) 1.39 0.47, 4.07 0.17
Race (white vs non-white) 2.78 0.84, 9.20 0.40
Clinical Peripheral neuropathy (yes vs no) 3.81 1.28, 11.35 0.02
Overweight or obese (BMI ≥25 vs <25 kg/m2) 0.11 0.04, 0.36 <0.001
Number of comorbidities 0.76 0.63, 0.92 0.02
Symptom severity Bloating 0.62 0.42, 0.91 0.02
GERD 1.70 1.08, 2.67 0.02
*A total of 136 diabetic patients with delayed emptying were included in the analysis: T1DM = 78, T2DM = 58; one T2DM patient has missing data
for the GERD subscale on enrollment. †p derived from a backward stepwise multiple logistic model regressing diabetes subtype (T1DM vs T2DM on
the candidate set of 46 baseline predictors included in Tables 1 and 2 (p for exclusion = 0.05), where age, sex, and white race were forced into the
model. GCSI was not included due to collinearity with its components. One measure of inflammation was used (either a high CRP and/or a high
ESR). Total numbers of comorbidities were included instead of individual comorbidities. A two category symptom duration (≥5 vs <5 years) was used
due to small numbers in the categories. Final model is presented. Hosmer–Lemeshow Goodness of fit v2 (df = 86) = 3.77, p = 0.71.
Bold values represent statistical significance p ≤ 0.05.
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Factors associated with changes in gastroparesis-
related outcomes at 48-weeks Multiple regression
analyses were used to assess the relationship of eight
clinical factors to outcomes at 48 weeks in the T1DM
and T2DM groups with gastroparesis (Table 6). T1DM
patients were less likely to report decreased vomiting
(OR = 0.21, 95% CI: 0.05–0.87; p = 0.03), but more
likely to have reductions in loss of appetite scores
(OR = 4.25, 95% CI: 1.07–16.92; p = 0.04) compared to
T2DM patients. When data from both diabetic sub-
types were pooled, no reduction in any parameter of
gastroparesis severity was related to initial HbA1c
levels or presence of peripheral neuropathy on enroll-
ment (Table S3). Except for decreases in abdominal
pain scores in T2DM patients whose HbA1c increased
over 48 weeks (p = 0.02), changes in symptom severity
over 48 weeks were similar in T1DM and T2DM
patients whose HbA1c levels either worsened or
decreased (Table S4). Reduction or no reduction in
HbA1c levels did not vary significantly between
diabetic subgroups over the 48-week period (data not
shown).
Table 5 Comparison of 48 week changes in severity, healthcare use, psychological function, and quality of life in T1DM vs T2DM
Category Characteristic













vs baseline) 95% CI p value†
Clinical BMI (kg/m2) 27.2 0.67 0.18, 1.53 0.12 34.1 0.55 0.32, 1.42 0.21 0.44
Hemoglobin
A1c (%)
8.1 0.47 0.32, 1.27 0.23 7.2 0.44 0.03, 0.92 0.07 0.51
Gastroparesis
severity
Investigator-rated 2.5 0.33 0.57, 0.09 0.009 2.2 0.30 0.55, 0.05 0.02 0.23
Medications Prokinetics 70.5% 15.9% 2.8, 30.0% 0.01 71.7% 8.7% 3.6, 21.0% 0.22 1.00




81.8% 13.6% 1.2, 26.0% 0.03 80.4% 4.3% 6.3, 15.0% 0.63 1.00
NSAIDs 52.3% 2.3% 21.8, 17.2% 1.00 76.1% 17.4% 35.9, 1.1% 0.08 0.21
Opiates 47.7% 13.6% 2.1, 29.4% 0.11 43.5% 17.4% 1.3, 33.4% 0.04 0.84
Pain modulators 29.6% 4.5% 10.3, 19.3% 0.73 34.8% 2.2% 13.9, 9.5% 1.00 0.43
Antidepressants 40.9% 9.1% 8.4, 26.6% 0.39 39.1% 13.1% 5.8, 31.8% 0.21 0.91
Anxiolytics 15.9% 25.0% 9.9, 40.1% 0.001 21.7% 2.1% 17.1, 12.8% 1.00 1.00
Antidiabetics 93.2% 0% 2.3, 2.3% 1.00 95.3% 2.2% 13.9, 9.5% 1.00 1.00




in past year (%)




4.8 1.55 3.16, 0.07 0.06 2.4 0.74 2.22, 0.74 0.32 0.70
Number of
ED visits
NA 4.86 2.78, 6.95 NA NA 2.46 1.04, 3.88 NA 0.07
% on TPN 4.5% 2.3% 7.7, 12.2% 1.00 8.7% 8.7% 19.0, 1.6% 0.13 0.13
% undergoing
GES
11.4% 20.5% 4.73, 36.2% 0.01 0.0% 10.9% 0.3, 22.0% 0.06 0.16
Psychological
function
BDI 21.3 1.18 4.91, 2.56 0.53 18.8 0.51 2.42, 3.44 0.73 0.69
Y1 state anxiety 44.4 0.85 3.96, 5.66 0.72 44.4 0.64 3.70, 4.99 0.77 0.97
Y2 trait anxiety 44.1 2.20 1.80, 6.20 0.27 44.0 0.58 3.26, 4.42 0.77 0.53
Quality
of life
PAGI-QOL 2.5 0.22 0.14, 0.58 0.22 2.6 0.15 0.11, 0.42 0.25 0.84
SF-36v2 physical 32.6 1.28 1.72, 4.27 0.39 29.7 1.82 0.52, 4.16 0.12 0.80
SF-36v2 mental 35.3 1.55 2.95, 6.05 0.49 36.6 0.65 2.96, 4.26 0.72 0.86
*N determined by value for medication or outcome being available at enrollment and at 48 weeks; for T1DM, between 31 and 44; for T2DM, between
36 and 46. †Mean change of outcome or % medication use (48 weeks—baseline) or mean number of events in 48 weeks for ED visits, since baseline
for ED visits unavailable. For continuous outcomes, p value determined using one sample t-test of the null hypothesis of no difference in means at
follow-up and baseline. For binary outcomes (hospitalized, TPN, GES) and medication use, an exact McNemar’s test for paired proportions was used
to determine p, and 95% confidence intervals (CI) determined using a continuity correction. ‡p values for continuous outcomes determined using
multiple regression of each outcome in relation to diabetes subtype with adjustment for the baseline value of the outcome. p value for ED visits was
determined using a negative binomial with robust variance to account for overdispersion. p values for binary outcomes and medication use were
derived from Wald tests to assess whether change in medication use varied by diabetes subtype using conditional logistic regression. Unconditional
exact logistic regression was used to assess changes in TPN use or GES implantation, since no T2DM patients had those treatments at either
enrollment (GES) or 48 weeks (TPN). §Total hospitalizations for gastroparesis since baseline exclude GES placement. NA was defined as not
applicable (the number of ED visits in the past year was not queried at baseline).
Bold values represent statistical significance p ≤ 0.05.
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DISCUSSION
Our findings delineate many clinical similarities in
patients with T1DM and T2DM and gastroparesis and
confirm several demographic differences. Gastroin-
testinal symptoms rated at baseline were remarkably
similar in intensity between diabetic subtypes, includ-
ing nausea and stomach fullness, with only greater
bloating in T2DM patients and increased GERD in
T1DM patients being significantly different. Our
results also showed the HbA1c levels and the severity
of gastric emptying delay did not correlate with the
symptoms associated with gastroparesis in either
patients with T1DM or T2DM; even though gastric
retention severity was higher in T1DM, symptoms
were not correspondingly increased at enrollment.
The poor relation of symptom severity to gastric
emptying in T1DM vs T2DM patients is consistent
with recent literature, and suggests other pathophysi-
ologic abnormalities mediate GI symptom genesis.8,44
Factors such as poor fundic accommodation, height-
ened sensitivity to gastric distention, gastric dysrhyth-
mias, and pyloric dysfunction warrant study as
potential causes of GI symptoms associated with
diabetic gastroparesis.45–47
Despite reporting similar GI symptom intensity as
T2DM patients, hospitalizations for gastroparesis and
for GES implantations were higher in T1DM patients
at baseline. It is likely that factors other than GI
symptoms such as poor glycemic control, and dehy-



























































































































P = 0.28 0.30 0.36 0.59 0.62 0.42 0.24 0.06 0.78 0.79 0.20
0.0060.850.040.030.090.040.0020.030.0050.01P = 0.009
A Type 1 diabetics gastroparesis symptom severity
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Change in symptom severity over 48 weeks
Figure 1 Patient-rated symptom scores at
baseline and at 48-week follow-up. (A)
T1DM patients exhibited moderate to severe
baseline symptom severities (clear bars; data
expressed as mean  upper limit of 95% CI).
Symptom scores did not decrease over
48 weeks (dark bars). (B) T2DM patients
exhibited baseline symptom severities in the
moderate to severe range (clear bars).
However, a reduction in symptoms was
observed at 48 weeks for all symptoms
except postprandial fullness and visible
distention (dark bars). (C) Mean changes in
symptoms  95% CI are plotted with p
values for baseline vs 48-week values for
T1DM and T2DM patients. No symptom
changed significantly for T1DM patients.
Overall symptom scores decreased and 8 of
10 individual symptoms significantly
decreased in T2DM gastroparetics at 48-
week follow-up (all p ≤ 0.05). *means
p ≤ 0.05.
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acute vomiting may be more relevant drivers of
hospitalizations in T1DM patients. Despite this greater
resource use in T1DM, overall medication use profiles
and quality of life scores were similar to T2DM
gastroparetics at baseline.
The clinical perception that patients with T1DM
and gastroparesis are frequently underweight is not
supported by our findings. We found almost half of
T1DM patients with gastroparesis were overweight or
obese and only 3% were underweight, while T2DM
patients with gastroparesis were even heavier as in
prior reports.19,20 Baseline TPN use was noted by less
than 10% of patients in both subgroups reflecting the
ability of most patients to sustain intake by oral or
enteral routes. However, these findings do not rule out
significant nutritional impairments. Our group previ-
ously reported mean daily caloric intakes of less than
1200 calories with deficiencies in essential nutrients
including vitamin B6, vitamin K, and iron in patients
with gastroparesis.48
An infectious prodrome was noted in 14% of T1DM
and T2DM patients. A similar incidence of infectious
prodrome has been observed with idiopathic gastro-
paresis, suggestive of a potential viral etiology in these
non-diabetic patients.8 The role of infections as cofac-
tors in triggering the onset of diabetic gastroparesis
could be the focus of additional study.
A new finding of this investigation is the difference
in GI symptoms in the two groups at the 48-week
follow-up visits. Symptom scores decreased only in the
T2DM patients while symptom severity was mostly
unchanged in those with T1DM. It is possible the lack
of reduction in GI symptom scores at 48 weeks in
T1DM patients may reflect irreversible diabetes-
related damage to the stomach wall. However, in
ultrastructural studies from full-thickness gastric biop-
sies, no differences were observed in the loss of enteric
neurons, depletion of interstitial cells of Cajal, or in
myenteric immune cell infiltration in specimens from
T1DM vs T2DM patients.49 This differential outcome
in GI symptoms in T1DM vs T2DM patients occurred
despite aggressive management over the 48 weeks of
follow-up. Patients with T1DM more often were
prescribed prokinetic agents, proton pump inhibitors,
and anxiolytics, and had more GES implants compared
with T2DM patients. These interventions had little
Table 6 Relative odds of change in clinical 48 week outcomes in relation to diabetes subtype (T1DM vs T2DM) in patients with gastroparesis






N (% improved) OR† 95% CI p value‡
Clinical
measures
BMI (kg/m2) (same or lower vs higher BMI) 42 (31%) 44 (27%) 1.86 0.51, 6.80 0.35
Hemoglobin A1c (%) (any decrease) 28 (25%) 36 (42%) 0.80 0.19, 3.30 0.76
Gastroparesis
severity
Investigator-rated severity (≥1 point decrease) 43 (33%) 46 (37%) 0.68 0.21, 2.13 0.50
Patient-rated (any decrease) Overall GCSI 40 (60%) 45 (62%) 1.10 0.32, 3.71 0.88
Nausea 40 (35%) 45 (51%) 0.54 0.18, 1.64 0.28
Retching 40 (48%) 45 (56%) 0.45 0.10, 2.10 0.31
Vomiting 40 (33%) 45 (53%) 0.21 0.05, 0.87 0.03
Stomach fullness 40 (40%) 45 (44%) 1.71 0.53, 5.53 0.37
Unable to finish meal 40 (35%) 45 (42%) 1.13 0.33, 3.81 0.85
Postprandial fullness 40 (48%) 45 (40%) 2.65 0.78, 9.02 0.12
Loss of appetite 40 (50%) 45 (42%) 4.25 1.07, 16.92 0.04
Bloating 40 (38%) 45 (40%) 1.68 0.50, 5.63 0.40
Visible distention 40 (30%) 45 (36%) 1.15 0.32, 4.13 0.83
Upper abdominal pain 40 (38%) 45 (47%) 1.81 0.48, 6.75 0.38
Health care
utilization
Hospitalizations for gastroparesis (none over 48 weeks
vs any)
44 (45%) 46 (65%) 0.85 0.26, 2.77 0.78
ED visits (none over 48 weeks vs any) 44 (27%) 46 (50%) 0.43 0.14, 1.29 0.13
Psychological
function
BDI (≤5 point decrease) 40 (35%) 45 (40%) 0.91 0.28, 2.90 0.87
Y1 state anxiety (any decrease) 40 (45%) 45 (49%) 0.85 0.25, 2.95 0.80
Y2 trait anxiety (any decrease) 40 (38%) 45 (49%) 0.45 0.14, 1.44 0.18
Quality
of life
PAGI-QOL (any increase) 39 (51%) 43 (56%) 0.87 0.29, 2.54 0.80
SF-36v2 physical (≥1 point increase) 40 (50%) 43 (53%) 1.70 0.50, 5.81 0.40
SF-36v2 mental (≥1 point increase) 40 (53%) 43 (51%) 1.19 0.39, 3.66 0.76
*Each outcome indicator is defined as change in the characteristic score at 48 weeks compared to baseline. Outcome indicators based on change in
value at 48 weeks from value at enrollment included: symptom score reduction (any decrease in total GCSI or in individual GCSI scores), BMI (same
or lower), hemoglobin A1c (any decrease), psychological function (BDI decreased by 5 or more points; Y1 state-anxiety, Y2 trait-anxiety any decrease),
and QOL (PAGI-QOL any increase; SF-36v2 physical and SF-36v2 mental components, increase in at least one point). †OR = Relative odds of change
in T1DM vs T2DM. ‡OR’s derived from logistic regression models of each indicator of change in characteristic score at 48 weeks in relation to
diabetes type and baseline value of the indicator. Models included a propensity score to adjust the diabetes type effect for the probability of being
T1DM based on age, sex, and race (white vs not white).
Bold values represent statistical significance p ≤ 0.05.
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positive impact on the symptoms in the T1DM
subgroup, suggesting these patients had a refractory
and end-stage condition. However, investigator ratings
of gastroparesis severity improved in both diabetic
groups at 48 weeks; it is possible that this divergence
of clinician and patient ratings stemmed from
decreases in the hospitalizations observed in T1DM
patients. Nevertheless, future studies of investiga-
tional therapies of diabetic gastroparesis may need to
consider differential responses in the two subtypes.
Our results showed no relationship between HbA1c
levels and patient-reported GCSI scores or investigator-
rated gastroparesis severity at 48 weeks. Furthermore,
the decrease in GI symptoms reported by the T2DM
patients occurred even though HbA1c values increased
slightly over the 48 weeks. Thus, chronic glycemic
control did not appear to influence GI symptoms in
either group of diabetic patients with gastroparesis.
Efforts for tighter glycemic control in patients with
long-standing diabetes are important for many reasons,
but these findings suggest that symptom reductions
(particularly in T2DM patients) can occur without
improved glucose control. Ongoing studies employing
intensive insulin therapy will more rigorously deter-
mine if improved glycemia has additional symptom
benefits. Although the presence of peripheral neuropa-
thy was a discriminator of gastroparesis in T1DM vs
T2DM on regression analysis, neuropathy did not
relate to GCSI scores suggesting that peripheral and
visceral complications of diabetes may not necessarily
be linked. This finding also raises the possibility that
gastroparesis in diabetes is not primarily neuropathic
in origin, as suggested by histopathologic investiga-
tions performed by the GpCRC.26
Medication use over 48 weeks differed in the dia-
betic subtypes. Nearly half of the patients in the
subgroups were receiving opioid agents at baseline, but
T2DM patients more often were given new opiate
prescriptions over 48 weeks of follow-up. Abdominal
pain is the predominant symptom in 20% of gastro-
paresis patients, irrespective of etiology.4 The mecha-
nisms for abdominal pain and the reasons for starting
narcotics in T2DM patients are likely to be multifac-
torial; these could not be discerned from our analyses.
In general, opiates slow gastric emptying and may
worsen symptoms associated with gastroparesis. How-
ever, the reductions in GI symptom scores in the
T2DM patients suggest that narcotics did not adversely
affect these patients from an overall perspective. Many
oral antidiabetic drugs such as metformin can cause
nausea and vomiting.25 Unexpectedly, metformin use
was actually associated with less vomiting in T2DM
patients. Nevertheless, metformin intake should be
considered among the causes of unexplained GI symp-
toms in T2DM patients.
Psychological dysfunction and quality of life are
poor in patients with gastroparesis.11 These measures
were equally poor in T1DM and T2DM patients at
baseline, although more T1DM patients had severe
anxiety. Psychological and quality of life parameters
remained unchanged at 48 weeks of follow-up despite
decreases in GI symptom scores in gastroparesis
patients with T2DM. These findings suggest that GI
symptom severity is not the only factor influencing
either psychological distress or poor quality of life, at
least in T2DM patients.
Gastric electrical stimulator therapy was employed
more often for gastroparesis in T1DM patients com-
pared to T2DM patients, but the T1DM group did not
report a decrease in GI symptoms. Although differ-
ences did not reach significance, GES use also was
higher over 48 weeks in the T2DM patients
(change = 11%, p = 0.06). Gastric electrical stimulator
therapy decreases nausea and vomiting in some but not
all studies of diabetic gastroparesis.50 Future controlled
investigations assessing GES efficacy in diabetic gas-
troparesis should be performed to contrast benefits in
T1DM vs T2DM patients.
Our study had some limitations. Firstly, determina-
tion of diabetic subtypewas dependent on subject report
and review of the medical records by the investigator.
Secondly, referral bias may have influenced the findings
because the patients were referred to the tertiary
motility centers of the GpCRC. Thus, our patients
may not reflect typical patients managed in the com-
munity and they may have had clinical features that
were unfavorable for symptom reductions over
48 weeks of follow-up. However, given the similarities
in baseline GI symptoms in the T1DM and T2DM
patients, it is likely referral bias was similar for both
diabetic subtypes. Nevertheless, more T1DM patients
had GES therapy which probably reflects the refractory
nature of symptoms in this group. Thirdly, assessments
of healthcare utilization did not include costs or address
length of stay, outpatient visits, and missed work.
Fourth, 48 weeks may be an inadequate time period to
detect symptom score reductions in T1DM patients or
differentiate resource utilization. The numbers of
patients available for study at 48 weeks may have
precluded some smaller differences not being detected;
however, our study had 80% power to detect a minimal
difference of 0.6 SD units in GCSI between the two
subtypes. Finally, we had some concerns about non-
significant trends to higher dropouts over 48 weeks of
follow-up in the T1DM patients. Although several
minor differences were observed in patients who did
K. L. Koch et al. Neurogastroenterology and Motility
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vs did not attend their 48 study visits, the lack of
relation of 48-week visit attendance and GCSI scores,
diabetes subtype, and hospitalizations confirmed that
the different outcomes of T1DM and T2DM patients
were not due to differential study compliance. We
believe these limitations are countered by the signifi-
cant strengths of the study including the large numbers
of patients with gastroparesis and T1DM and T2DM,
use of standardized tests and protocols and comprehen-
sive collection of clinical, psychological, quality of life,
and healthcare usage data.
In conclusion, our findings challenge several clinical
axioms about gastroparesis in the two diabetic sub-
types. Firstly, baseline GI symptoms associated with
gastroparesis were remarkably similar in T1DM vs
T2DM patients, even though T1DM patients had more
severe gastric emptying delays and higher HbA1c
values. These observations suggest that the presence
of other gastric or extragastric pathogenic factors may
mediate gastroparesis symptom severity. Secondly,
symptoms associated with gastroparesis in both dia-
betic subtypes did not correlate with HbA1c levels or
severity of gastroparesis; and last, after 48 weeks of
follow-up, most GI symptom scores decreased only in
T2DM patients even though T1DM patients showed
increased medical and surgical treatment utilization.
These similarities and differences in patients with
T1DM and T2DM form a basis for further research to
improve clinical outcomes with novel drugs, gastric
stimulation parameters, and insulin dosing regimens
for symptoms associated with gastroparesis.
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